Benjamin Bakall, MD, PhD

Benjamin Bakall, MD, PhD, weighs the RESTORE efficacy and safety data, the practical realities of in-office delivery, and how genotype-independent treatment reshapes candidacy and patient counseling.

Byron Lam, MD, and Benjamin Bakall, MD, PhD, discuss what an FDA approval of tinlarebant could mean for the Stargardt disease type 1 standard of care.

Bakall on 3-year REMAIN data for MCO-010 in retinitis pigmentosa: durable 3-line acuity gains, why genotype did not matter, and which patients responded best.

3-year REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of gene mutation, with no treatment-related serious adverse events, per Benjamin Bakall, MD, PhD, at ASRS 2026.